Plain-English translation of NCT04873492 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is trying to understand why multiple sclerosis (MS) affects people so differently — why some people have a mild course while others face rapid disability. Researchers will analyze blood samples from people who've had their first MS symptoms, comparing those who developed aggressive MS to those with milder disease, and also comparing both groups to healthy volunteers. By studying the immune cells and molecules in the blood, they hope to discover early warning signs that could predict how someone's MS will progress.
MS is unpredictable — some people stay relatively stable while others become disabled quickly. Currently, doctors can't reliably predict at diagnosis which path a patient will take. This study exists to find biological clues in the blood that could help identify aggressive cases early, so patients and doctors can make better treatment decisions from the start.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have a blood sample taken once — researchers will collect blood shortly after your first MS symptoms appear. For those already diagnosed with known MS outcomes, this is a one-time visit. For those newly diagnosed, you'll be followed over time so doctors can see how your MS progresses, with additional check-ins to assess your disease course. The study compares your blood results to healthy volunteers and other MS patients to identify patterns that predict aggressive versus milder disease.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France